Further preclinical studies including PDX in vivo animal models and clinical studies are warranted to explore the therapeutic benefits of targeting the PIN1/CDK1-pVHL axis in the treatment of multiple human cancers with wild-type VHL. This evidence concerns the gene PIN1 and cancer.